Market Entry Strategy & Prototype for PopulationLeap™ in the Immuno-Oncology Market

市场进入策略

• 批准号: 74090
• 金额: $ 12.2万
• 依托单位: TRAJECTURE LTD
• 依托单位国家: 英国
• 项目类别: Study
• 财政年份: 2020
• 资助国家: 英国
• 起止时间: 2020 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=74090
• 关键词: Market; Entry; Strategy; Prototype; PopulationLeap

We all understand each other to be unique. It is of little surprise that diseases such as Corona Virus affect people differently. In controlled studies otherwise health and identically selected people also show markedly differing immune responses. Having platform technologies that can repeatedly clarify what is happening at the molecular level in the immune system is important not just to understanding which patients will have poor outcomes from viral infections, but also who will response well or poorly to modern cancer treatments which use the immune system to attack the cancer cells.Current state-of-the-art technologies have mostly focussed on using larger numbers of patients with the hopes of extracting out meaning from the complex number of underlying molecular events that are involved. However, all have suffered from high level of base-line patient-to-patient variability.Our innovation takes a fundamentally different approach to those above. The innovation uses data algorithms to enable clearer read-out from deep sampling studies and identify biomarkers. We have developed the innovation from concept, own completely, and have already used it to reveal previous unknown details of therapeutics' action in in vitro systems, and in clinical blood sample analysis through collaborative projects.The platform has been packaged into a collaborative offering called PopulationLeap(tm), and Trajecture is currently collaborating with several organisations to develop the technology, which has brought new insight into immune response with implications for immune-oncology trials and understanding how otherwise identical people have markedly different immune responses.We seek funding to develop our market entry strategy to the economic problem of targeting immuno-therapies in a market expected to be worth $125-130Bn by 2026\.

我们都知道彼此是独一无二的。这是不足为奇的疾病，如冠状病毒影响不同的人。在对照研究中，健康的人和同样选择的人也表现出明显不同的免疫反应。拥有能够反复阐明免疫系统中分子水平上发生的事情的平台技术不仅对了解哪些患者会因病毒感染而预后不良很重要，而且也会对使用免疫系统攻击癌细胞的现代癌症治疗反应良好或较差。ART技术主要集中于使用大量的患者，希望从所涉及的复杂数量的潜在分子事件中提取出意义。然而，所有这些都受到高水平的基线患者间变异性的影响。我们的创新采取了与上述方法完全不同的方法。这项创新使用数据算法，从深度采样研究中获得更清晰的读数，并识别生物标志物。我们已经从概念上开发了创新，完全拥有，并已经通过合作项目将其用于揭示体外系统中治疗作用的先前未知细节，以及临床血液样本分析。该平台已打包成一个名为PopulationLeap（tm）的合作产品，Trajecture目前正在与几个组织合作开发该技术，这为免疫反应带来了新的见解，对免疫肿瘤学试验产生了影响，并了解了在其他方面相同的人如何具有明显不同的免疫反应。我们寻求资金，以制定我们的市场进入战略，以解决靶向免疫疗法的经济问题，预计到2026年，该市场将价值1250 - 1300亿美元。